trending Market Intelligence /marketintelligence/en/news-insights/trending/ArYfpYSzsVkTUfz6_tk7UQ2 content esgSubNav
In This List

Congo approves Merck vaccine in face of Ebola outbreak

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Congo approves Merck vaccine in face of Ebola outbreak

The Democratic Republic of the Congo approved the use of Merck & Co. Inc.'s experimental Ebola vaccine rVSV-ZEBOV to contain the virus' outbreak in the country, Reuters reported.

Although not licensed, Merck's vaccine was found to be highly protective against the deadly virus in a trial carried out on nearly 12,000 people in nearby Guinea in 2015.

The outbreak occurred in the northeast part of the country and has claimed four lives, with 52 suspected cases.